Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform Based on Artificial Intelligence Model Using Mathematical Analysis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- PreDiabetes
- Sponsor
- Pusan National University Hospital
- Enrollment
- 130
- Locations
- 1
- Primary Endpoint
- Number of Participants With Insulin Resistance
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to collect a variety of clinical data and blood glucose changes using a continuous glucose monitoring device for high-risk diabetes patients (prediabetes) in order to develop a personalized diabetes prevention and management platform based on artificial intelligence model using mathematical analysis.
Detailed Description
After being informed about the study and potential risks, all patients giving written informed consent wear a continuous glucose monitoring device ("iPro2" professional continuous glucose monitoring, MedtronicⓇ, California, USA) and smart band ("Fitbit Inspire HR", FitbitⓇ, California, USA) for 1 week. During this period, all patients are tested oral glucose tolerance test and take a standard diet (calorie calculated) at morning. The patient's data from this study is compared to a predicted values by mathematical analysis model for diabetes prevention.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Above 18 years old.
- •Prediabetes
- •Fasting plasma glucose : 100\~125mg/dL, fasting is defined as no caloric intake for at least 8 hours.
- •2-hour plasma glucose during 75g oral glucose tolerance test : 140 \~ 199mg/dL
- •Glycated hemoglobin(HbA1c) : 5.7\~6.4% (39-47mmol/mol)
Exclusion Criteria
- •with a history of newly diagnosed and treated cancer within the last 5 years
- •with a history of hospitalization for active disease within the last 3 months
- •with a history of severe cardiovascular disease within the last 3 months
- •with a history of steroid treatment in the last 3 months
- •people who have had major surgery planned within the last 3 months or who have had surgery within 3 months
- •people who are pregnant or have been in the last 3 months after giving birth
Outcomes
Primary Outcomes
Number of Participants With Insulin Resistance
Time Frame: 1 week
the prevalence of insulin resistance in participants was measured. Insulin resistance was calculated by HOMA-IR(homeostatic model assessment of insulin resistance), QUICKI (quantitative insulin sensitivity check index) and Matsuda index